2nd Quarter - Report — UCB, INC. for UCB, INC. (2022)

Firm

UCB, INC.

Client

UCB, INC.

Income

—

Expenses

$290,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; S. 464 - Safe Step Act; H.R. 7667 - Prescription Drug User Fee Amendments of 2022; H.R. 2163 - Safe Step Act; Prescription Drug User Fee Act; H.R. 7389 - MVP Act; Scheduled drug de-certification; Value based arrangements; House Epilepsy Caucus

Lobbyist	Covered position, as disclosed
JED PERRY	—

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2163 (117th), H.R. 7667 (117th), H.R. 7389 (117th), S. 4348 (117th), S. 464 (117th)

Taxation/Internal Revenue Code TAX

Corporate Tax Reform

Lobbyist	Covered position, as disclosed
JED PERRY	—

Contacted: SENATE

Medicare/Medicaid MMM

H.R. 7389 - MVP Act

Lobbyist	Covered position, as disclosed
JED PERRY	—

Contacted: HOUSE OF REPRESENTATIVES

Bills named: H.R. 7389 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.